To include your compound in the COVID-19 Resource Center, submit it here.

Lexicon's sotagliflozin increases risk of ketoacidosis in Phase III

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) said sotagliflozin (SAR439954) increased the risk of diabetic ketoacidosis (DKA) in the Phase III inTandem3 trial to treat Type I diabetes, which met its primary endpoint in June (see BioCentury, June 14).

In inTandem3, the rate of DKA in patients who received sotagliflozin plus insulin therapy for 24 weeks was 3% vs.

Read the full 559 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE